AllPennyStocks.com Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

Other Penny Stock Movers

Digestive Health Expansion Sends This Microcap Soaring
Utah Copper Explorer Jumps 19% on Surface Assays
Indonesian Gold Developer Jumps 27% as Ministry Moves File to Final Approval
Most Popular
{{ index + 1 }}


Back to Top